Patents by Inventor Georg Speck

Georg Speck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050107417
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein X? is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
    Type: Application
    Filed: July 15, 2004
    Publication date: May 19, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Sabine Germeyer, Christopher Meade, Helmut Meissner, Gerd Morschhaeuser, Michel Pairet, Sabine Pestel, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Ingo Konetzki
  • Publication number: 20050054664
    Abstract: A compound of formula 1 wherein: A is a group selected from X? is an anion with a single negative charge; R1 and R2 are each independently a C1-C4-alkyl optionally substituted with hydroxy or halogen; and R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen, with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.
    Type: Application
    Filed: October 21, 2004
    Publication date: March 10, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Helmut Meissner, Gerd Morschhaeuser, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Publication number: 20050042176
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein X? is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.
    Type: Application
    Filed: July 15, 2004
    Publication date: February 24, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Sabine Germeyer, Christopher Meade, Helmut Meissner, Gerd Morschhaeuser, Michel Pairet, Sabine Pestel, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Publication number: 20050043343
    Abstract: A pharmaceutical composition comprising: (a) a compound of formula 1 wherein X31 is an anion with a single negative charge; and (b) a PDE IV inhibitor, or an enantiomer, mixture of enantiomers, racemate, solvate, or hydrate thereof, processes for preparing them, and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: July 15, 2004
    Publication date: February 24, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Sabine Germeyer, Christopher Meade, Helmut Meissner, Gerd Morschhaeuser, Michel Pairet, Sabine Pestel, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Publication number: 20050038252
    Abstract: Difurylglycolic acid esters of the formula 1 wherein X? and the groups A, R, R1, R2, R3 and R3? may have the meanings given in the claims and in the specification, processes for preparing them and their use for treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract or menstrual pain.
    Type: Application
    Filed: September 23, 2004
    Publication date: February 17, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerd Morschhaeuser, Michael Pieper, Georg Speck
  • Patent number: 6852728
    Abstract: A compound of formula 1 wherein: A is a group selected from X? is an anion with a single negative charge; R1 and R2 are each independently a C1-C4-alkyl optionally substituted with hydroxy or halogen; and R3, R4, R5, R6, R7, and R8 are each independently hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, CF3, CN, NO2, or halogen, with the proviso that at least one of the groups R3, R4, R5, R6, R7, and R8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: February 8, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Helmut Meissner, Gerd Morschhaeuser, Michael Paul Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Publication number: 20050020622
    Abstract: Fluorenecarboxylic acid esters of general formula 1 wherein X? and the groups A, R, R1, R2, R3, R3?, R4, and R4? have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
    Type: Application
    Filed: August 9, 2004
    Publication date: January 27, 2005
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhaeuser, Sabine Pestel, Michael Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Patent number: 6815452
    Abstract: Fluorenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
    Type: Grant
    Filed: February 5, 2004
    Date of Patent: November 9, 2004
    Assignee: Boehringer Ingelheim Pharma KG & Co GmbH
    Inventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhaeuser, Sabine Pestel, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Patent number: 6790856
    Abstract: Flourenecarboxylic acid esters of general formula 1 wherein X− and the groups A, R, R1, R2, R3, R3′, R4, and R4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.
    Type: Grant
    Filed: January 2, 2003
    Date of Patent: September 14, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhaeuser, Sabine Pestel, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Patent number: 6780863
    Abstract: Compounds of which the following are exemplary: These have tryptase-inhibiting activity and are useful for the treatment of inflammatory and allergic disease conditions.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: August 24, 2004
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ralf Anderskewitz, Christine Braun, Rainer Hamm, Bernd Disse, Hans Michael Jennewein, Georg Speck
  • Publication number: 20040157832
    Abstract: Fluorenecarboxylic acid esters of general formula 1 1
    Type: Application
    Filed: February 5, 2004
    Publication date: August 12, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Sabine Germeyer, Helmut Meissner, Gerd Morschhauser, Sabine Pestel, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck
  • Publication number: 20040132760
    Abstract: A compound of formula 1 1
    Type: Application
    Filed: November 20, 2003
    Publication date: July 8, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Steffen Breitfelder, Matthias Hoffmann, Matthias Grauert, Michael P. Pieper, Georg Speck
  • Patent number: 6747044
    Abstract: The invention relates to new compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1 denotes 3-hydroxypropyl, 1,3-dihydroxyprop-2-yl or C3-C6-cycloalkylmethyl, and R2, R3, R4 and Ar have the meanings given in the specification, as well as the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: June 8, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Horst Dollinger, Franz Esser, Birgit Jung, Kurt Schromm, Georg Speck
  • Publication number: 20040087617
    Abstract: The present invention relates to new anticholinergics of general formula 1 1
    Type: Application
    Filed: October 14, 2003
    Publication date: May 6, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Helmut Meissner, Gerd Morschhaeuser, Michael Paul Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Rolf Banholzer
  • Patent number: 6706726
    Abstract: The present invention relates to new anticholinergics of general formula 1: wherein A, X− and the groups R1, R2, R3, R4, R5, R6 and R7 may have the meanings given in the claims and in the specification, processes for preparing them and their use as pharamaceutical compositions.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: March 16, 2004
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Helmut Meissner, Gerd Morschhaeuser, Michael Paul Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Rolf Banholzer
  • Patent number: 6696462
    Abstract: A compound of formula 1 wherein: X- is an anion with a single negative charge; A and B, which are identical or different, are each —O—, —S—, —NH—, —CH2—, —CH═CH—, or —N(C1-C4-alkyl)—; R is hydrogen, hydroxy, —C1-C4-alkyl, —C1-C4-alkyloxy, —C1-C4-alkylene-halogen, —0—C1-C4-alkylene-halogen, —C1-C4-alkylene-OH, —CF3, —CHF2, —C1-C4-alkylene-C1-C4-alkyloxy, —0—COC1-C4-alkyl, —0—COC1-C4-alkylene-halogen, —C1-C4-alkylene-C3-C6-cycloalkyl, —0—COCF3, or halogen; R1 and R2, which are identical or different, are each —C1-C5-alkyl, which is optionally substituted by —C3-C6-cycloalkyl, hydroxy, or halogen, or R1 and R2 together are a —C3-C5-alkylene bridge; R3, R4, R3′, and R4′, which are identical or different, are each hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, —CF3, —CHF2, &mdas
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: February 24, 2004
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christian Eickmeier, Sabine Germeyer, Matthias Grauert, Sabine Pestel, Michael P. Pieper, Georg Speck, Steffen Breitfelder
  • Publication number: 20040010003
    Abstract: A pharmaceutical composition comprising:
    Type: Application
    Filed: March 24, 2003
    Publication date: January 15, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet, Ingo Konetzki
  • Publication number: 20040002502
    Abstract: The present invention relates to novel pharmaceutical compositions based on a new anticholinergic 1 and heterocyclic compounds 2, processes for preparing them and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: April 8, 2003
    Publication date: January 1, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
  • Patent number: 6664253
    Abstract: The invention relates to new compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, X and Ar1 have the meanings given in the specification, as well as the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: December 16, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Horst Dollinger, Franz Esser, Birgit Jung, Gerd Schnorrenberg, Kurt Schromm, Georg Speck
  • Publication number: 20030229227
    Abstract: Difurylglycolic acid esters of the formula 1 1
    Type: Application
    Filed: March 4, 2003
    Publication date: December 11, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerd Morschhaeuser, Michael P. Pieper, Georg Speck